Showing results (91-100 of 639) with videos related to
Sort By:
Pageof 64
Therapeutic Advances in Musculoskeletal Disease|July 20, 2018
Improving drug adherence in osteoporosis: an update on more recent studiesAyesha Jaleel, Kenneth G Saag, Maria I DanilaRheumatic Diseases Clinics of North America|October 26, 2011
Long-term safety concerns of antiresorptive therapyJie Zhang, Kenneth G Saag, Jeffrey R CurtisTherapeutic Advances in Musculoskeletal Disease|October 1, 2019
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practiceGiovanni Adami, Elizabeth J Rahn, Kenneth G SaagCurrent Osteoporosis Reports|November 28, 2019
Pragmatic Clinical Trials in OsteoporosisGiovanni Adami, Kenneth G Saag, Maria I DanilaCurrent Rheumatology Reports|November 14, 2013
Osteopenia: debates and dilemmasJie Zhang, Sarah L Morgan, Kenneth G SaagCurrent Rheumatology Reports|October 16, 2014
Cardiovascular risk and the use of biologic agents in rheumatoid arthritisDebbie T Lim, Amy C Cannella, Kaleb D Michaud, et al.Arthritis Care & Research|February 12, 2016
Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical TrialsPriyanka Vashisht, Harlan Sayles, Amy C Cannella, et al.BMJ (Clinical Research Ed.)|April 25, 2018
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implicationsBryant R England, Geoffrey M Thiele, Daniel R Anderson, et al.The Journal of Rheumatology|August 17, 2019
Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout CohortJasvinder A Singh, Shuo Yang, Kenneth G SaagArthritis Research & Therapy|November 21, 2013
Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplastyKaleb Michaud, Edward V Fehringer, Kevin Garvin, et al.Pageof 64